/
Infectious Disease
COVID-19
256
Pipeline Programs↗
165
Active Trials↗
250
Companies Involved↗
COVID-19 is a highly competitive landscape with 256 programs across 250 companies. The most active players are WestVac Biopharma Co., Ltd., BioNTech, Vanda Pharmaceuticals. 41 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical168
Phase 114
Phase 233
Phase 341
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
139 of 185 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 185 classified programs, each share of the total. Modality classified for 98% of 256 pipeline programs.
Analysis
Trial Status
2,779
clinical trials
Completed1,319 · 47%
Unknown status652 · 23%
Terminated376 · 14%
Withdrawn219 · 8%
Active, not recruiting74 · 3%
Recruiting64 · 2%
Other75 · 3%
Clinical Trials
Trial Activity
2779 trials
A Phase 1 Open-Label Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike, A Next-Generation SARS-CoV-2 Booster Vaccine Via Intranasal and Inhalational Routes, in Previously Vaccinated Adults
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07536308·80 enrolled
Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections
Recruiting·—·Preclinical·NCT07610967·130 enrolled
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
Recruiting·—·Preclinical·NCT06810934·80 enrolled
Page 1 of 186
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)